Updated:
Vernalis
Vernalis is a other based in Cambridge; the Altss profile covers its classification, headquarters, registration, AUM band, and key contacts for private-markets...
Vernalis
Vernalis collaborates with a wide range of organisations to enable drug discovery programs through both short- and long-term projects
General information
Firm type
other
Location
Region
North America
Country
United Kingdom
City
Cambridge
Corporate office
Granta Park, Great Abington, Cambridge CB21 6GB, United Kingdom
Additional offices
Pleasant Hill, United States · Herzliya, Israel · New York, United States · Dubai, United Arab Emirates
Principals
James Murray
Head of Research
Clare Searle
Finance Director
Susan Wallcraft
General Counsel
Ben Davis
Business Development
Kerry
Business Development
Lisa Baker
Project Leader
James Davidson
Director of Chemistry
Sector focus
Frequently asked questions
Who runs investment decisions at Vernalis?
Vernalis operates as a contract research organization, not an investment firm. Dr. James Murray serves as Head of Research, overseeing drug discovery programs. There is no investment committee or allocation function.
How does Vernalis source its drug discovery projects?
Vernalis partners with pharmaceutical and biotechnology companies through short- and long-term collaborations, often targeting challenging therapeutic targets such as protein-protein interactions. It also benefits from its position as part of the HitGen Group, which provides access to DNA-encoded library (DEL) technology.
Is Vernalis structured as a single family office or does it operate more like a venture firm?
Neither — Vernalis is a contract research organization (CRO) that provides drug discovery services. It does not manage assets or invest capital on behalf of a family or external LPs.
Does Vernalis participate in fund commitments or only direct deals?
Vernalis does not make fund commitments or direct investments. Its business model is fee-for-service research collaborations with pharma and biotech companies.
What investment stages does Vernalis typically target?
Vernalis does not target investment stages. It offers a full drug development pipeline from gene discovery to candidate selection, including hit identification, lead optimization, and pre-clinical studies.
How is Vernalis related to HitGen Group?
Vernalis is part of the HitGen Group, a publicly traded company (HitGen Inc., listed on the Shanghai Stock Exchange) specializing in DNA-encoded library technology. This affiliation gives Vernalis access to HitGen's proprietary DEL platform.
Where does the underlying wealth come from?
This is not applicable — Vernalis is a CRO, not a wealth-managing entity. It does not have a disclosed wealth origin.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: